US Sales
$517M
+20.3% YoY
US business grew 20.3% YoY to $517M, driven by specialty portfolio and lenalidomide.
SUNPHARMA
Healthcare
14 Nov 2024
Sunpharma Ltd — Q2 FY25
Sun Pharma delivered a strong Q2 FY25 with consolidated sales of INR 13,264 crore, up 10.5% YoY, driven by US specialty growth (+20.3% to $517M) and India formulation growth (+11%).
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Sun Pharma delivered a strong Q2 FY25 with consolidated sales of INR 13,264 crore, up 10.5% YoY, driven by US specialty growth (+20.3% to $517M) and India formulation growth (+11%). EBITDA margin expanded 350 bps YoY to 29.6%, aided by favorable product mix and lower material costs. PAT grew 28% YoY to INR 3,040 crore. The US specialty portfolio (Ilumya, Winlevi, Cequa) continues to perform well, while the India business gained market share to 8.1%. R&D spend guidance was revised down to 7-8% of sales due to clinical trial delays. Key risks include the binary outcome of Leqselvi patent litigation and potential margin pressure from higher selling expenses.
सन फार्मा की दूसरी तिमाही (Q2 FY25) में अच्छी कमाई हुई। कंपनी की कुल बिक्री 13,264 करोड़ रुपये रही, जो पिछले साल से 10.5% ज्यादा है। अमेरिका में खास दवाओं की बिक्री 20.3% बढ़कर 517 मिलियन डॉलर हुई, और भारत में दवाओं की बिक्री 11% बढ़ी। कंपनी का मुनाफा (EBITDA) 29.6% हो गया, जो पिछले साल से 3.5% ज्यादा है, क्योंकि उन्होंने सही उत्पाद मिश्रण और कम लागत का फायदा उठाया। शुद्ध मुनाफा (PAT) 28% बढ़कर 3,040 करोड़ रुपये हो गया। अमेरिका में Ilumya, Winlevi, Cequa जैसी दवाएं अच्छा कर रही हैं, और भारत में बाजार हिस्सेदारी 8.1% हो गई। R&D खर्च अब बिक्री का 7-8% रहेगा, क्योंकि कुछ परीक्षणों में देरी हुई। जोखिम: Leqselvi पेटेंट मुकदमे का नतीजा और बिक्री खर्च बढ़ने से मुनाफा कम हो सकता है।
Key Numbers
India Market Share
8.1%
+40bps YoY
Sun Pharma's market share in the Indian pharma market increased to 8.1% from 7.7%.
Global Specialty Sales
$286M
+19.2% YoY
Global specialty sales grew 19.2% YoY to $286M, led by Ilumya and other key brands.
India Volume Growth
5.2%
+450bps vs IPM
Sun's volume growth in India was 5.2% vs IPM's 0.7%, driven by new launches and field force expansion.
What Changed vs Last Quarter
NEW
Leqselvi launch readiness within weeks of favorable judgment
Management stated they would be ready to launch Leqselvi within a couple of weeks post a favorable court ruling on the patent litigation.
NEW
Ilumya PsA Phase III data expected H2 CY2025
Phase III data for Ilumya in psoriatic arthritis is expected in the second half of calendar year 2025, with launch shortly after approval.
UPDATED
R&D spend to be 7-8% of sales for FY25
R&D spend for FY25 is expected to be in the range of 7-8% of sales, down from earlier guidance of 8-10%, due to delays in clinical studies.
DROPPED
Effective tax rate to increase on full-year basis
Tax rate expected to rise due to expiry of certain exemptions; should be viewed on an annualized basis.
DROPPED
Leqselvi launch pending court decision on preliminary injunction
Launch timing of Leqselvi will be governed by court ruling on Incyte's motion; company opposes and seeks early outcome.
NEW RISK
Leqselvi patent litigation binary outcome
The Leqselvi launch depends on a favorable court ruling on the '335 patent; an unfavorable outcome could delay launch until patent expiry in Dec 2026.
NEW RISK
R&D spend may remain below guidance if trials delay further
Management acknowledged that further delays in clinical trials could keep R&D spend below the revised 7-8% guidance.
NEW RISK
Higher selling expenses pressuring margins
Other expenses rose significantly due to higher selling and distribution costs in US and EM, which could pressure margins if not offset by revenue growth.
NEW RISK
Japan price cuts impacting ROW revenues
Price cuts in Japan are expected to continue pressuring ROW revenues for the next few quarters, as mentioned by management.
RISK GONE
Leqselvi launch delay due to litigation
Incyte filed a preliminary injunction motion to block Leqselvi launch; outcome uncertain and could delay revenue contribution.
RISK GONE
Halol plant re-audit timeline uncertain
Management plans to request FDA re-audit once ready, but no specific timeline provided; pending approvals may impact U.S. generic pipeline.
RISK GONE
U.S. generic revenue flat despite Revlimid contribution
U.S. generic sales were flat sequentially; Revlimid contribution was not large this quarter, and sustainability is uncertain.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY24
Tax rate expected to rise due to expiry of certain exemptions; should be viewed on an annualized basis.
Mentioned in Q1 FY24, Q2 FY24
Management aims to grow India formulation business faster than the Indian pharmaceutical market on an annualized basis.
Mentioned in Q1 FY24, Q3 FY24
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
Mentioned in Q2 FY24, Q4 FY24
Stelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.
Management Guidance
R&D spend to be 7-8% of sales for FY25
R&D spend for FY25 is expected to be in the range of 7-8% of sales, down from earlier guidance of 8-10%, due to delays in clinical studies.
Management guidance growthLeqselvi launch readiness within weeks of favorable judgment
Management stated they would be ready to launch Leqselvi within a couple of weeks post a favorable court ruling on the patent litigation.
Management guidance otherIlumya PsA Phase III data expected H2 CY2025
Phase III data for Ilumya in psoriatic arthritis is expected in the second half of calendar year 2025, with launch shortly after approval.
Management guidance growthKey Risks
Leqselvi patent litigation binary outcome
The Leqselvi launch depends on a favorable court ruling on the '335 patent; an unfavorable outcome could delay launch until patent expiry in Dec 2026.
high · analyst_questionR&D spend may remain below guidance if trials delay further
Management acknowledged that further delays in clinical trials could keep R&D spend below the revised 7-8% guidance.
medium · management_commentaryHigher selling expenses pressuring margins
Other expenses rose significantly due to higher selling and distribution costs in US and EM, which could pressure margins if not offset by revenue growth.
medium · data_observationJapan price cuts impacting ROW revenues
Price cuts in Japan are expected to continue pressuring ROW revenues for the next few quarters, as mentioned by management.
medium · management_commentaryNotable Quotes
Our focus was on generating a more profitable prescription. I think we've been able to achieve that.
We are very excited. Only issue is how fast can we bring the product to market, and what kind of clinical outcome benefit we are able to show while the product is in registration.
I think any biosimilar will go after the big fish, and not necessarily where the space that we are playing.
Frequently Asked Questions
What was Sunpharma's revenue in Q2 FY25?
Sunpharma reported revenue of ₹13,264 Cr in Q2 FY25, representing a +10.5% change compared to the same quarter last year.
What guidance did Sunpharma management give for FY26?
R&D spend to be 7-8% of sales for FY25: R&D spend for FY25 is expected to be in the range of 7-8% of sales, down from earlier guidance of 8-10%, due to delays in clinical studies. Leqselvi launch readiness within weeks of favorable judgment: Management stated they would be ready to launch Leqselvi within a couple of weeks post a favorable court ruling on the patent litigation. Ilumya PsA Phase III data expected H2 CY2025: Phase III data for Ilumya in psoriatic arthritis is expected in the second half of calendar year 2025, with launch shortly after approval.
What are the key risks for Sunpharma in FY26?
Key risks include Leqselvi patent litigation binary outcome — The Leqselvi launch depends on a favorable court ruling on the '335 patent; an unfavorable outcome could delay launch until patent expiry in Dec 2026.; R&D spend may remain below guidance if trials delay further — Management acknowledged that further delays in clinical trials could keep R&D spend below the revised 7-8% guidance.; Higher selling expenses pressuring margins — Other expenses rose significantly due to higher selling and distribution costs in US and EM, which could pressure margins if not offset by revenue growth.; Japan price cuts impacting ROW revenues — Price cuts in Japan are expected to continue pressuring ROW revenues for the next few quarters, as mentioned by management..
Did Sunpharma meet its previous quarter's guidance?
Of 2 tracked promises, management 0 met, 0 close, 2 missed.
Where can I read the full Sunpharma Q2 FY25 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.